NCT00750724

Brief Summary

OA knee is a common degenerative diseases of the joint.

  • There are many methods to treat this condition.
  • Hyaluronic acid is one of the recomended treatment of OA knee.
  • There is no any study on MRI change after injection hyaluronic acid.
  • The Hypothesis is 25 mg of sodium hyaluronate (2.5 ml) would preserve the joint space in patient with osteoarthritis of the knee compared to placebo .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jul 2008

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 10, 2008

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

May 26, 2010

Status Verified

July 1, 2009

Enrollment Period

1.2 years

First QC Date

September 9, 2008

Last Update Submit

May 25, 2010

Conditions

Keywords

Hyaluronic acid,OA knee,MRI

Outcome Measures

Primary Outcomes (1)

  • MRI will be analysed with semiquantitative whole organ scoring method (WORMS) c

    6 months

Secondary Outcomes (1)

  • WOMAC, VAS, side effects

    14 months

Study Arms (2)

B

PLACEBO COMPARATOR

2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks

Drug: normal saline,2 ml., intraarticular weekly for 5 weeks

A

EXPERIMENTAL

2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks

Drug: 25 mg sodium hyaluronate "GO ON"

Interventions

25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks

A

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Ambulatory non pregnant females and males 40-\<80 years of age.
  • Subjects who withdraw pain medication or nutritional supplements for symptom relief for OA hand for a total of at least 30 days before screening visit 0.
  • Pain at or below 40 mm on a 100 mm VAS in the index knee joints.
  • A documented diagnosis of OA of the knee joint, or meeting American College of Rheumatology (ACR) clinical criteria for classification of idiopathic (primary) OA for at least 6 months prior to screening.
  • Subject has been documented radiographic evidence of OA of the knees from the screening Visit radiograph of grade 2 or 3 according to Kellgren and Lawrence Radiographic Grading.
  • Subject has no any contraindication for MRI
  • Subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment.

You may not qualify if:

  • Subjects with history of hypersensitivity to hyaluronate.
  • Subjects with skin lesion at the knee joint.
  • A history of knee surgery within 6 months prior to screening V0.
  • Significant prior injury to the knee joint within 12 months prior to screening V0.
  • Disease of the spine or other lower extremity joints of sufficient degree to affect the knee joint.
  • Treatment with other drugs potentially affecting bone or cartilage metabolism as described below:
  • chronic systematic corticosteroids
  • Diacerin or glucosamine treatment within the last 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weerachai Kosuwon

Khon Kaen, Changwat Khon Kaen, 40001, Thailand

Location

MeSH Terms

Conditions

OsteoarthritisOsteoarthritis, Knee

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Weerachai Kosuwon, Professor

    Faculty of Medicine, Khon Kaen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 9, 2008

First Posted

September 10, 2008

Study Start

July 1, 2008

Primary Completion

September 1, 2009

Study Completion

October 1, 2009

Last Updated

May 26, 2010

Record last verified: 2009-07

Locations